Rhythm Pharmaceuticals (RYTM) Receives Daily Coverage Optimism Rating of 0.09

Headlines about Rhythm Pharmaceuticals (NASDAQ:RYTM) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.5608338226028 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Rhythm Pharmaceuticals (NASDAQ RYTM) opened at $26.35 on Friday. Rhythm Pharmaceuticals has a 12 month low of $21.38 and a 12 month high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.40) by ($1.38). equities research analysts expect that Rhythm Pharmaceuticals will post -1.63 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on the stock. BidaskClub cut shares of Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 29th. Needham & Company LLC assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $32.00 target price for the company. Cowen reiterated a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th. Bank of America assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Morgan Stanley assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued an “equal weight” rating and a $23.00 target price for the company. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $31.25.

ILLEGAL ACTIVITY WARNING: “Rhythm Pharmaceuticals (RYTM) Receives Daily Coverage Optimism Rating of 0.09” was first published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/rhythm-pharmaceuticals-rytm-receives-daily-coverage-optimism-rating-of-0-09/1886567.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.